Burlingame-Based Igenica Lands $33 Million in Third Round

Burlingame, Calif. -- Igenica, a Burlingame-based biopharmaceutical firm developing antibodies for the treatment of cancer, said on Tuesday it has raised $33 million in its third round of funding, led by new investor Third Rock Ventures. Previous backers The Column Group, Orbimed Advisors and 5AM Ventures also participated in the round, which increased the company's total funding to $55 million since its launch in 2009. Igenica said it will use the proceeds to advance its monoclonal antibody pipeline toward clinical trials. "Third Rock's investment highlights the broad potential of Igenica's antibody technology and provides strategic flexibility as we execute our operating and business plans," said David Goeddel, the company's executive chairman
http://www.igenica.com 
http://www.sacbee.com/2012/06/12/4555748/igenica-closes-33-million-in-series.html